Recursion Book Value Per Share from 2010 to 2024

RXRX Stock

USD 5.70 0.05 0.87%

Recursion Pharmaceuticals Book Value Per Share yearly trend continues to be fairly stable with very little volatility. Book Value Per Share is likely to outpace its year average in 2024. Book Value Per Share is the ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of Recursion Pharmaceuticals according to its financial statements. View All Fundamentals

Book Value Per Share

First Reported

2010-12-31

Previous Quarter

2.22962591

Current Value

2.34

Quarterly Volatility

1.58625548

Credit Downgrade

Yuan Drop

Covid

Check Recursion Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Recursion Pharmaceuticals' main balance sheet or income statement drivers, such as Net Interest Income of 19.1 M, Interest Income of 19.2 M or Depreciation And Amortization of 25.6 M, as well as many indicators such as Price To Sales Ratio of 43.68, Dividend Yield of 0.0 or PTB Ratio of 4.64. Recursion financial statements analysis is a perfect complement when working with Recursion Pharmaceuticals Valuation or Volatility modules.

Check out the analysis of Recursion Pharmaceuticals Correlation against competitors.

For more information on how to buy Recursion Stock please use our How to Invest in Recursion Pharmaceuticals guide.

Latest Recursion Pharmaceuticals' Book Value Per Share Growth Pattern

Below is the plot of the Book Value Per Share of Recursion Pharmaceuticals over the last few years. It is the ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements. Recursion Pharmaceuticals' Book Value Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Recursion Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 1.83 X

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Book Value Per Share

Timeline

Recursion Book Value Per Share Regression Statistics

	Arithmetic Mean	0.12
	Coefficient Of Variation	1,332
	Mean Deviation	1.34
	Median	(0.75)
	Standard Deviation	1.59
	Sample Variance	2.52
	Range	4.4329
	R-Value	0.72
	Mean Square Error	1.31
	R-Squared	0.52
	Significance	0
	Slope	0.25
	Total Sum of Squares	35.23

Recursion Book Value Per Share History

	2024	2.34
	2023	2.23
	2022	2.77
	2021	3.19
	2020	-1.24

Other Fundumenentals of Recursion Pharmaceuticals

Tangible Book Value Per Share

Recursion Pharmaceuticals Book Value Per Share component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Long Term Debt	Net Receivables	Total Liab	Net Invested Capital	Short Long Term Debt	Total Current Assets	Net Working Capital	Short Term Debt	Property Plant Equipment	Current Deferred Revenue	Good Will	Intangible Assets	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Common Stock
Total Assets		0.95	0.94	-0.96	-0.88	0.94	-0.98	0.78	-0.25	0.95	0.04	0.99	0.98	0.85	0.89	0.8	0.57	0.54	-0.5	-0.5	-0.5	-0.5
Total Stockholder Equity	0.95		0.97	-0.85	-0.82	0.94	-0.97	0.86	-0.54	1.0	-0.24	0.93	0.92	0.78	0.84	0.73	0.51	0.48	-0.44	-0.44	-0.44	-0.44
Net Tangible Assets	0.94	0.97		-0.86	-0.91	0.92	-0.99	0.82	-0.51	0.97	-0.25	0.92	0.9	0.79	0.93	0.75	0.69	0.66	-0.65	-0.65	-0.65	-0.65
Net Debt	-0.96	-0.85	-0.86		0.86	-0.92	0.92	-0.62	0.05	-0.84	-0.16	-0.96	-0.94	-0.88	-0.89	-0.87	-0.54	-0.51	0.51	0.51	0.51	0.51
Retained Earnings	-0.88	-0.82	-0.91	0.86		-0.88	0.9	-0.56	0.24	-0.82	0.11	-0.82	-0.79	-0.89	-0.99	-0.8	-0.88	-0.86	0.82	0.82	0.82	0.82
Accounts Payable	0.94	0.94	0.92	-0.92	-0.88		-0.94	0.64	-0.37	0.94	-0.2	0.91	0.87	0.94	0.92	0.92	0.57	0.54	-0.49	-0.49	-0.49	-0.49
Long Term Debt	-0.98	-0.97	-0.99	0.92	0.9	-0.94		-0.83	0.41	-0.97	0.13	-0.96	-0.95	-0.81	-0.92	-0.77	-0.63	-0.61	0.59	0.59	0.59	0.59
Net Receivables	0.78	0.86	0.82	-0.62	-0.56	0.64	-0.83		-0.57	0.86	-0.13	0.82	0.84	0.38	0.57	0.32	0.31	0.29	-0.3	-0.3	-0.3	-0.3
Total Liab	-0.25	-0.54	-0.51	0.05	0.24	-0.37	0.41	-0.57		-0.54	0.88	-0.23	-0.23	-0.11	-0.29	-0.14	-0.17	-0.16	0.16	0.16	0.16	0.16
Net Invested Capital	0.95	1.0	0.97	-0.84	-0.82	0.94	-0.97	0.86	-0.54		-0.24	0.93	0.92	0.78	0.84	0.73	0.51	0.48	-0.44	-0.44	-0.44	-0.44
Short Long Term Debt	0.04	-0.24	-0.25	-0.16	0.11	-0.2	0.13	-0.13	0.88	-0.24		0.09	0.12	-0.06	-0.17	-0.13	-0.16	-0.15	0.15	0.15	0.15	0.15
Total Current Assets	0.99	0.93	0.92	-0.96	-0.82	0.91	-0.96	0.82	-0.23	0.93	0.09		1.0	0.79	0.84	0.75	0.48	0.46	-0.45	-0.45	-0.45	-0.45
Net Working Capital	0.98	0.92	0.9	-0.94	-0.79	0.87	-0.95	0.84	-0.23	0.92	0.12	1.0		0.74	0.8	0.71	0.45	0.42	-0.43	-0.43	-0.43	-0.43
Short Term Debt	0.85	0.78	0.79	-0.88	-0.89	0.94	-0.81	0.38	-0.11	0.78	-0.06	0.79	0.74		0.9	0.95	0.64	0.63	-0.52	-0.52	-0.52	-0.52
Property Plant Equipment	0.89	0.84	0.93	-0.89	-0.99	0.92	-0.92	0.57	-0.29	0.84	-0.17	0.84	0.8	0.9		0.86	0.82	0.81	-0.79	-0.79	-0.79	-0.79
Current Deferred Revenue	0.8	0.73	0.75	-0.87	-0.8	0.92	-0.77	0.32	-0.14	0.73	-0.13	0.75	0.71	0.95	0.86		0.51	0.49	-0.45	-0.45	-0.45	-0.45
Good Will	0.57	0.51	0.69	-0.54	-0.88	0.57	-0.63	0.31	-0.17	0.51	-0.16	0.48	0.45	0.64	0.82	0.51		1.0	-0.95	-0.95	-0.95	-0.95
Intangible Assets	0.54	0.48	0.66	-0.51	-0.86	0.54	-0.61	0.29	-0.16	0.48	-0.15	0.46	0.42	0.63	0.81	0.49	1.0		-0.95	-0.95	-0.95	-0.95
Long Term Debt Total	-0.5	-0.44	-0.65	0.51	0.82	-0.49	0.59	-0.3	0.16	-0.44	0.15	-0.45	-0.43	-0.52	-0.79	-0.45	-0.95	-0.95		1.0	1.0	1.0
Capital Surpluse	-0.5	-0.44	-0.65	0.51	0.82	-0.49	0.59	-0.3	0.16	-0.44	0.15	-0.45	-0.43	-0.52	-0.79	-0.45	-0.95	-0.95	1.0		1.0	1.0
Deferred Long Term Liab	-0.5	-0.44	-0.65	0.51	0.82	-0.49	0.59	-0.3	0.16	-0.44	0.15	-0.45	-0.43	-0.52	-0.79	-0.45	-0.95	-0.95	1.0	1.0		1.0
Common Stock	-0.5	-0.44	-0.65	0.51	0.82	-0.49	0.59	-0.3	0.16	-0.44	0.15	-0.45	-0.43	-0.52	-0.79	-0.45	-0.95	-0.95	1.0	1.0	1.0

Click cells to compare fundamentals

About Recursion Pharmaceuticals Financial Statements

Recursion Pharmaceuticals investors use historical fundamental indicators, such as Recursion Pharmaceuticals' Book Value Per Share, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Recursion Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Book Value Per Share	2.23	2.34
Tangible Book Value Per Share	1.80	0.92

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Recursion Stock Analysis

When running Recursion Pharmaceuticals' price analysis, check to measure Recursion Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Recursion Pharmaceuticals is operating at the current time. Most of Recursion Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Recursion Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Recursion Pharmaceuticals' price. Additionally, you may evaluate how the addition of Recursion Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC